Global Influenza Antiviral Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Published: November 2022

No. of Pages: 121

Price:

Single User License: US $ 5600

Corporate User License: US $ 11200

Report Description
Table of Contents

Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Influenza Antiviral Drugs estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Influenza Antiviral Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Influenza Antiviral Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Influenza Antiviral Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Influenza Antiviral Drugs include GSK, Boehringer Ingelheim, Merck, Novartis, Beximco Pharmaceuticals, Pfizer, Roche, Johnson & Johnson and Sanofi, etc. In 2021, the global top five players had a share approximately % in terms of revenue.

Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Influenza Antiviral Drugs companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Influenza Antiviral Drugs market. Further, it explains the major drivers and regional dynamics of the global Influenza Antiviral Drugs market and current trends within the industry.

Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
- GSK
- Boehringer Ingelheim
- Merck
- Novartis
- Beximco Pharmaceuticals
- Pfizer
- Roche
- Johnson & Johnson
- Sanofi
- Cipla Limited
- Natco Pharma
- Seqirus
- Adamas Pharmaceuticals, Inc.
- Teva Pharmaceuticals
- Daiichi Sankyo Company

Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Influenza Antiviral Drugs Segment by Type
- Oseltamivir
- Zanamivir
- Peramivir
- Adamantanes
- Others
Influenza Antiviral Drugs Segment by Application
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Pharmacies
- Others

Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
- North America
- - United States
- - Canada
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- - Nordic Countries
- - Rest of Europe
- Asia-Pacific
- - China
- - Japan
- - South Korea
- - Southeast Asia
- - India
- - Australia
- - Rest of Asia
- Latin America
- - Mexico
- - Brazil
- - Rest of Latin America
- Middle East & Africa
- - Turkey
- - Saudi Arabia
- - UAE
- - Rest of MEA

Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Influenza Antiviral Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:
This report presents an overview of global market for Influenza Antiviral Drugs market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Influenza Antiviral Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Influenza Antiviral Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Influenza Antiviral Drugs revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Influenza Antiviral Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Influenza Antiviral Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GSK, Boehringer Ingelheim, Merck, Novartis, Beximco Pharmaceuticals, Pfizer, Roche, Johnson & Johnson and Sanofi, etc.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Influenza Antiviral Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Oseltamivir
1.2.3 Zanamivir
1.2.4 Peramivir
1.2.5 Adamantanes
1.2.6 Others
1.3 Market by Application
1.3.1 Global Influenza Antiviral Drugs Market Growth Rate by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Pharmacies
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Influenza Antiviral Drugs Market Size (2017-2028)
2.2 Influenza Antiviral Drugs Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Influenza Antiviral Drugs Market Size by Region (2017-2022)
2.4 Global Influenza Antiviral Drugs Market Size Forecast by Region (2023-2028)
2.5 Global Top Influenza Antiviral Drugs Countries Ranking by Market Size
3 Influenza Antiviral Drugs Competitive by Company
3.1 Global Influenza Antiviral Drugs Revenue by Players
3.1.1 Global Influenza Antiviral Drugs Revenue by Players (2017-2022)
3.1.2 Global Influenza Antiviral Drugs Market Share by Players (2017-2022)
3.2 Global Influenza Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Influenza Antiviral Drugs Revenue
3.4 Global Influenza Antiviral Drugs Market Concentration Ratio
3.4.1 Global Influenza Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Influenza Antiviral Drugs Revenue in 2021
3.5 Global Influenza Antiviral Drugs Key Players Head office and Area Served
3.6 Key Players Influenza Antiviral Drugs Product Solution and Service
3.7 Date of Enter into Influenza Antiviral Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Influenza Antiviral Drugs Breakdown Data by Type
4.1 Global Influenza Antiviral Drugs Historic Revenue by Type (2017-2022)
4.2 Global Influenza Antiviral Drugs Forecasted Revenue by Type (2023-2028)
5 Global Influenza Antiviral Drugs Breakdown Data by Application
5.1 Global Influenza Antiviral Drugs Historic Market Size by Application (2017-2022)
5.2 Global Influenza Antiviral Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Influenza Antiviral Drugs Revenue by Company (2020-2022)
6.2 North America Influenza Antiviral Drugs Revenue by Type (2017-2028)
6.3 North America Influenza Antiviral Drugs Revenue by Application (2017-2028)
6.4 North America Influenza Antiviral Drugs Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Influenza Antiviral Drugs Revenue by Company (2020-2022)
7.2 Europe Influenza Antiviral Drugs Revenue by Type (2017-2028)
7.3 Europe Influenza Antiviral Drugs Revenue by Application (2017-2028)
7.4 Europe Influenza Antiviral Drugs Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Influenza Antiviral Drugs Revenue by Company (2020-2022)
8.2 Asia Pacific Influenza Antiviral Drugs Revenue by Type (2017-2028)
8.3 Asia Pacific Influenza Antiviral Drugs Revenue by Application (2017-2028)
8.4 Asia Pacific Influenza Antiviral Drugs Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Influenza Antiviral Drugs Revenue by Company (2020-2022)
9.2 Latin America Influenza Antiviral Drugs Revenue by Type (2017-2028)
9.3 Latin America Influenza Antiviral Drugs Revenue by Application (2017-2028)
9.4 Latin America Influenza Antiviral Drugs Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Influenza Antiviral Drugs Revenue by Company (2020-2022)
10.2 Middle East and Africa Influenza Antiviral Drugs Revenue by Type (2017-2028)
10.3 Middle East and Africa Influenza Antiviral Drugs Revenue by Application (2017-2028)
10.4 Middle East and Africa Influenza Antiviral Drugs Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Influenza Antiviral Drugs Products and Services
11.1.4 GSK Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.1.5 GSK Influenza Antiviral Drugs SWOT Analysis
11.1.6 GSK Recent Developments
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Details
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Influenza Antiviral Drugs Products and Services
11.2.4 Boehringer Ingelheim Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.2.5 Boehringer Ingelheim Influenza Antiviral Drugs SWOT Analysis
11.2.6 Boehringer Ingelheim Recent Developments
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Influenza Antiviral Drugs Products and Services
11.3.4 Merck Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.3.5 Merck Influenza Antiviral Drugs SWOT Analysis
11.3.6 Merck Recent Developments
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Influenza Antiviral Drugs Products and Services
11.4.4 Novartis Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.4.5 Novartis Influenza Antiviral Drugs SWOT Analysis
11.4.6 Novartis Recent Developments
11.5 Beximco Pharmaceuticals
11.5.1 Beximco Pharmaceuticals Company Details
11.5.2 Beximco Pharmaceuticals Business Overview
11.5.3 Beximco Pharmaceuticals Influenza Antiviral Drugs Products and Services
11.5.4 Beximco Pharmaceuticals Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.5.5 Beximco Pharmaceuticals Influenza Antiviral Drugs SWOT Analysis
11.5.6 Beximco Pharmaceuticals Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Influenza Antiviral Drugs Products and Services
11.6.4 Pfizer Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.6.5 Pfizer Influenza Antiviral Drugs SWOT Analysis
11.6.6 Pfizer Recent Developments
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Influenza Antiviral Drugs Products and Services
11.7.4 Roche Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.7.5 Roche Influenza Antiviral Drugs SWOT Analysis
11.7.6 Roche Recent Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Details
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Influenza Antiviral Drugs Products and Services
11.8.4 Johnson & Johnson Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.8.5 Johnson & Johnson Influenza Antiviral Drugs SWOT Analysis
11.8.6 Johnson & Johnson Recent Developments
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Influenza Antiviral Drugs Products and Services
11.9.4 Sanofi Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.9.5 Sanofi Influenza Antiviral Drugs SWOT Analysis
11.9.6 Sanofi Recent Developments
11.10 Cipla Limited
11.10.1 Cipla Limited Company Details
11.10.2 Cipla Limited Business Overview
11.10.3 Cipla Limited Influenza Antiviral Drugs Products and Services
11.10.4 Cipla Limited Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.10.5 Cipla Limited Influenza Antiviral Drugs SWOT Analysis
11.10.6 Cipla Limited Recent Developments
11.11 Natco Pharma
11.11.1 Natco Pharma Company Details
11.11.2 Natco Pharma Business Overview
11.11.3 Natco Pharma Influenza Antiviral Drugs Products and Services
11.11.4 Natco Pharma Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.11.5 Natco Pharma Recent Developments
11.12 Seqirus
11.12.1 Seqirus Company Details
11.12.2 Seqirus Business Overview
11.12.3 Seqirus Influenza Antiviral Drugs Products and Services
11.12.4 Seqirus Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.12.5 Seqirus Recent Developments
11.13 Adamas Pharmaceuticals, Inc.
11.13.1 Adamas Pharmaceuticals, Inc. Company Details
11.13.2 Adamas Pharmaceuticals, Inc. Business Overview
11.13.3 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Products and Services
11.13.4 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.13.5 Adamas Pharmaceuticals, Inc. Recent Developments
11.14 Teva Pharmaceuticals
11.14.1 Teva Pharmaceuticals Company Details
11.14.2 Teva Pharmaceuticals Business Overview
11.14.3 Teva Pharmaceuticals Influenza Antiviral Drugs Products and Services
11.14.4 Teva Pharmaceuticals Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.14.5 Teva Pharmaceuticals Recent Developments
11.15 Daiichi Sankyo Company
11.15.1 Daiichi Sankyo Company Company Details
11.15.2 Daiichi Sankyo Company Business Overview
11.15.3 Daiichi Sankyo Company Influenza Antiviral Drugs Products and Services
11.15.4 Daiichi Sankyo Company Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022)
11.15.5 Daiichi Sankyo Company Recent Developments
12 Influenza Antiviral Drugs Market Dynamics
12.1 Influenza Antiviral Drugs Market Trends
12.2 Influenza Antiviral Drugs Market Drivers
12.3 Influenza Antiviral Drugs Market Challenges
12.4 Influenza Antiviral Drugs Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Tables
Table 1. Global Influenza Antiviral Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Oseltamivir
Table 3. Key Players of Zanamivir
Table 4. Key Players of Peramivir
Table 5. Key Players of Adamantanes
Table 6. Key Players of Others
Table 7. Global Influenza Antiviral Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Influenza Antiviral Drugs Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 9. Global Influenza Antiviral Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 10. Global Influenza Antiviral Drugs Revenue Market Share by Region (2017-2022)
Table 11. Global Influenza Antiviral Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 12. Global Influenza Antiviral Drugs Market Share by Players (2017-2022)
Table 13. Global Top Influenza Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Antiviral Drugs as of 2021)
Table 14. Ranking of Global Top Influenza Antiviral Drugs Companies by Revenue (US$ Million) in 2021
Table 15. Global 5 Largest Players Market Share by Influenza Antiviral Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 16. Key Players Headquarters and Area Served
Table 17. Key Players Influenza Antiviral Drugs Product Solution and Service
Table 18. Date of Key Manufacturers Enter into Influenza Antiviral Drugs Market
Table 19. Mergers & Acquisitions, Expansion Plans
Table 20. Global Influenza Antiviral Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 21. Global Influenza Antiviral Drugs Revenue Market Share by Type (2017-2022)
Table 22. Global Influenza Antiviral Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 23. Global Influenza Antiviral Drugs Revenue Market Share by Type (2023-2028)
Table 24. Global Influenza Antiviral Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 25. Global Influenza Antiviral Drugs Revenue Market Share by Application (2017-2022)
Table 26. Global Influenza Antiviral Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 27. Global Influenza Antiviral Drugs Revenue Market Share by Application (2023-2028)
Table 28. North America Influenza Antiviral Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 29. North America Influenza Antiviral Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 30. North America Influenza Antiviral Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 31. North America Influenza Antiviral Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 32. North America Influenza Antiviral Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 33. North America Influenza Antiviral Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 34. North America Influenza Antiviral Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 35. Europe Influenza Antiviral Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 36. Europe Influenza Antiviral Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 37. Europe Influenza Antiviral Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 38. Europe Influenza Antiviral Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 39. Europe Influenza Antiviral Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 40. Europe Influenza Antiviral Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 41. Europe Influenza Antiviral Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 42. Asia Pacific Influenza Antiviral Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 43. Asia Pacific Influenza Antiviral Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 44. Asia Pacific Influenza Antiviral Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 45. Asia Pacific Influenza Antiviral Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 46. Asia Pacific Influenza Antiviral Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 47. Asia Pacific Influenza Antiviral Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 48. Asia Pacific Influenza Antiviral Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 49. Latin America Influenza Antiviral Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 50. Latin America Influenza Antiviral Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 51. Latin America Influenza Antiviral Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 52. Latin America Influenza Antiviral Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 53. Latin America Influenza Antiviral Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 54. Latin America Influenza Antiviral Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 55. Latin America Influenza Antiviral Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Influenza Antiviral Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 57. Middle East and Africa Influenza Antiviral Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Influenza Antiviral Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Influenza Antiviral Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Influenza Antiviral Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Influenza Antiviral Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Influenza Antiviral Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 63. GSK Company Details
Table 64. GSK Business Overview
Table 65. GSK Influenza Antiviral Drugs Product and Services
Table 66. GSK Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 67. GSK Influenza Antiviral Drugs SWOT Analysis
Table 68. GSK Recent Developments
Table 69. Boehringer Ingelheim Company Details
Table 70. Boehringer Ingelheim Business Overview
Table 71. Boehringer Ingelheim Influenza Antiviral Drugs Product and Services
Table 72. Boehringer Ingelheim Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 73. Boehringer Ingelheim Influenza Antiviral Drugs SWOT Analysis
Table 74. Boehringer Ingelheim Recent Developments
Table 75. Merck Company Details
Table 76. Merck Business Overview
Table 77. Merck Influenza Antiviral Drugs Product and Services
Table 78. Merck Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 79. Merck Influenza Antiviral Drugs SWOT Analysis
Table 80. Merck Recent Developments
Table 81. Novartis Company Details
Table 82. Novartis Business Overview
Table 83. Novartis Influenza Antiviral Drugs Product and Services
Table 84. Novartis Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 85. Novartis Influenza Antiviral Drugs SWOT Analysis
Table 86. Novartis Recent Developments
Table 87. Beximco Pharmaceuticals Company Details
Table 88. Beximco Pharmaceuticals Business Overview
Table 89. Beximco Pharmaceuticals Influenza Antiviral Drugs Product and Services
Table 90. Beximco Pharmaceuticals Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 91. Beximco Pharmaceuticals Influenza Antiviral Drugs SWOT Analysis
Table 92. Beximco Pharmaceuticals Recent Developments
Table 93. Pfizer Company Details
Table 94. Pfizer Business Overview
Table 95. Pfizer Influenza Antiviral Drugs Product and Services
Table 96. Pfizer Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 97. Pfizer Influenza Antiviral Drugs SWOT Analysis
Table 98. Pfizer Recent Developments
Table 99. Roche Company Details
Table 100. Roche Business Overview
Table 101. Roche Influenza Antiviral Drugs Product and Services
Table 102. Roche Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 103. Roche Influenza Antiviral Drugs SWOT Analysis
Table 104. Roche Recent Developments
Table 105. Johnson & Johnson Company Details
Table 106. Johnson & Johnson Business Overview
Table 107. Johnson & Johnson Influenza Antiviral Drugs Product and Services
Table 108. Johnson & Johnson Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 109. Johnson & Johnson Influenza Antiviral Drugs SWOT Analysis
Table 110. Johnson & Johnson Recent Developments
Table 111. Sanofi Company Details
Table 112. Sanofi Business Overview
Table 113. Sanofi Influenza Antiviral Drugs Product and Services
Table 114. Sanofi Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 115. Sanofi Influenza Antiviral Drugs SWOT Analysis
Table 116. Sanofi Recent Developments
Table 117. Cipla Limited Company Details
Table 118. Cipla Limited Business Overview
Table 119. Cipla Limited Influenza Antiviral Drugs Product and Services
Table 120. Cipla Limited Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 121. Cipla Limited Influenza Antiviral Drugs SWOT Analysis
Table 122. Cipla Limited Recent Developments
Table 123. Natco Pharma Company Details
Table 124. Natco Pharma Business Overview
Table 125. Natco Pharma Influenza Antiviral Drugs Product and Services
Table 126. Natco Pharma Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 127. Natco Pharma Recent Developments
Table 128. Seqirus Company Details
Table 129. Seqirus Business Overview
Table 130. Seqirus Influenza Antiviral Drugs Product and Services
Table 131. Seqirus Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 132. Seqirus Recent Developments
Table 133. Adamas Pharmaceuticals, Inc. Company Details
Table 134. Adamas Pharmaceuticals, Inc. Business Overview
Table 135. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Product and Services
Table 136. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 137. Adamas Pharmaceuticals, Inc. Recent Developments
Table 138. Teva Pharmaceuticals Company Details
Table 139. Teva Pharmaceuticals Business Overview
Table 140. Teva Pharmaceuticals Influenza Antiviral Drugs Product and Services
Table 141. Teva Pharmaceuticals Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 142. Teva Pharmaceuticals Recent Developments
Table 143. Daiichi Sankyo Company Company Details
Table 144. Daiichi Sankyo Company Business Overview
Table 145. Daiichi Sankyo Company Influenza Antiviral Drugs Product and Services
Table 146. Daiichi Sankyo Company Influenza Antiviral Drugs Revenue in Influenza Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 147. Daiichi Sankyo Company Recent Developments
Table 148. Influenza Antiviral Drugs Market Trends
Table 149. Influenza Antiviral Drugs Market Drivers
Table 150. Influenza Antiviral Drugs Market Challenges
Table 151. Influenza Antiviral Drugs Market Restraints
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Influenza Antiviral Drugs Sales Market Share by Type: 2021 VS 2028
Figure 2. Oseltamivir Features
Figure 3. Zanamivir Features
Figure 4. Peramivir Features
Figure 5. Adamantanes Features
Figure 6. Others Features
Figure 7. Global Influenza Antiviral Drugs Sales Market Share by Application: 2021 VS 2028
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Ambulatory Surgical Centers Case Studies
Figure 11. Pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Influenza Antiviral Drugs Report Years Considered
Figure 14. Global Influenza Antiviral Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Influenza Antiviral Drugs Market Size 2017-2028 (US$ Million)
Figure 16. Global Influenza Antiviral Drugs Market Size Market Share by Region: 2021 VS 2028
Figure 17. Global Influenza Antiviral Drugs Revenue Market Share by Region in 2017 VS 2022
Figure 18. Global Top 10 Influenza Antiviral Drugs Countries Ranking by Market Size (US$ Million) in 2021
Figure 19. Global Influenza Antiviral Drugs Market Share by Players in 2021
Figure 20. Global Top Influenza Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Antiviral Drugs as of 2021)
Figure 21. The Top 10 and 5 Players Market Share by Influenza Antiviral Drugs Revenue in 2021
Figure 22. North America Influenza Antiviral Drugs Revenue Market Share by Company in 2021
Figure 23. North America Influenza Antiviral Drugs Revenue Market Share by Type (2017-2028)
Figure 24. North America Influenza Antiviral Drugs Revenue Market Share by Application (2017-2028)
Figure 25. North America Influenza Antiviral Drugs Revenue Share by Country (2017-2028)
Figure 26. U.S. Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 27. Canada Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 28. Europe Influenza Antiviral Drugs Revenue Market Share by Company in 2021
Figure 29. Europe Influenza Antiviral Drugs Revenue Market Share by Type (2017-2028)
Figure 30. Europe Influenza Antiviral Drugs Revenue Market Share by Application (2017-2028)
Figure 31. Europe Influenza Antiviral Drugs Revenue Share by Country (2017-2028)
Figure 32. Germany Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 33. France Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 34. U.K. Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 35. Italy Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 36. Russia Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 37. Asia Pacific Influenza Antiviral Drugs Revenue Market Share by Company in 2021
Figure 38. Asia Pacific Influenza Antiviral Drugs Revenue Market Share by Type (2017-2028)
Figure 39. Asia Pacific Influenza Antiviral Drugs Revenue Market Share by Application (2017-2028)
Figure 40. Asia Pacific Influenza Antiviral Drugs Revenue Share by Region (2017-2028)
Figure 41. China Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 42. Japan Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 43. South Korea Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 44. India Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 45. Australia Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 46. Taiwan Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 47. Indonesia Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 48. Thailand Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 49. Malaysia Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 50. Philippines Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 51. Vietnam Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 52. Latin America Influenza Antiviral Drugs Revenue Market Share by Company in 2021
Figure 53. Latin America Influenza Antiviral Drugs Revenue Market Share by Type (2017-2028)
Figure 54. Latin America Influenza Antiviral Drugs Revenue Market Share by Application (2017-2028)
Figure 55. Latin America Influenza Antiviral Drugs Revenue Share by Country (2017-2028)
Figure 56. Mexico Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 57. Brazil Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 58. Argentina Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 59. Middle East and Africa Influenza Antiviral Drugs Revenue Market Share by Company in 2021
Figure 60. Middle East and Africa Influenza Antiviral Drugs Revenue Market Share by Type (2017-2028)
Figure 61. Middle East and Africa Influenza Antiviral Drugs Revenue Market Share by Application (2017-2028)
Figure 62. Middle East and Africa Influenza Antiviral Drugs Revenue Share by Country (2017-2028)
Figure 63. Turkey Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 64. Saudi Arabia Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 65. UAE Influenza Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 66. GSK Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 67. Boehringer Ingelheim Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 68. Merck Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 69. Novartis Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 70. Beximco Pharmaceuticals Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 71. Pfizer Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 72. Roche Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 73. Johnson & Johnson Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 74. Sanofi Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 75. Cipla Limited Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 76. Natco Pharma Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 77. Seqirus Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 78. Adamas Pharmaceuticals, Inc. Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 79. Teva Pharmaceuticals Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 80. Daiichi Sankyo Company Revenue Growth Rate in Influenza Antiviral Drugs Business (2017-2022)
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed

Write comment about above report:

Published By: QYResearch Group

Product Code: QYResearch Group2105861

Related Reports

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Global Influenza Antiviral Drugs Market Growth (Status and Outlook) 2022-2028 As the global economy mends, the 2021 growth of Influenza Antiviral Drugs will have significant change from previous year. According to our (LP Information) latest study, the global Influenza Antiviral Drugs market size is USD million in 2022 from US...
Global Influenza (Flu) Antiviral Drugs Market Growth (Status and Outlook) 2022-2028 As the global economy mends, the 2021 growth of Influenza (Flu) Antiviral Drugs will have significant change from previous year. According to our (LP Information) latest study, the global Influenza (Flu) Antiviral Drugs market size is USD million in ...
Global Influenza (Flu) Antiviral Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028 Report Scope This latest report researches the industry structure, revenue and gross margin. Major players headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access...
Global Influenza (Flu) Antiviral Drugs Market Growth (Status and Outlook) 2020-2025 COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifti...

We are on:

Why ReportsnReports.com?

500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Delivery Time:
- Upto 24 hrs - working days
- Upto 48 hrs max - weekends and public holidays

Need Help?

Name *

Email *

Phone *

Country *

Subject *

Comments *